(UroToday.com) In conjunction with the Scientific Congress held as part of the American Society of Clinical Oncology’s Annual Meeting in May 2020, an Educational Symposium was convened on August 8 to 10th. In a session entitled “Too Many Choices: How to Select the Best Treatment for Your Patient With Kidney Cancer,” Primo Lara, MD, from UC Davis Comprehensive Cancer Center presented a plenary talk discussing the first-line treatment of metastatic renal cell carcinoma (mRCC), specifically addressing the question of whether combination therapy (with two agents) is better than monotherapy.